Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to facilitate patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in four simple steps:
On May 4th 2018, the first patient in Turkey was treated with QuiremSpheres® at the Florence Nightingale Hospital in Istanbul. Prof. Dr. Murat Cantaşdemir and
Terumo and Quirem Medical welcome an important milestone for QuiremSpheres® in the Netherlands and in Europe. QuiremSpheres® is now reimbursed for liver-dominant, non-resectable, colorectal liver
On 15 December 2017, the first patient was included in the HEPAR Primary study by Dr. Arthur J.A.T. Braat at UMC Utrecht, the Netherlands. The
We are happy to announce that QuiremSpheres® will be fully reimbursed in Belgium as of 1 October 2017. Jan Sigger, CEO of Quirem Medical B.V.,
The European launch of QuiremSpheres® was officially announced at CIRSE 2017 in Copenhagen, Denmark. QuiremSpheres® are now available to clinicians in various markets across Europe.